Skip to main content
. 2021 Nov 6;22(1):133. doi: 10.1186/s10194-021-01344-1

Table 1.

Patient characteristics

Patients
N = 542
Sex, n (%)
 Male 81 (15)
 Female 461 (85)
Migraine type, n (%)
 Chronic migraine 271 (50)
 Episodic migraine 271 (50)
Current dose of erenumab, n (%)
 70 mg 290 (54)
 140 mg 252 (46)
Insurance status, n (%)
 Statutory health insurance 474 (87)
 Private health insurance 68 (13)
 Treatment duration with erenumab in month, mean (SD) 6.9 (2.7)

SD standard deviation